Skip to main content
    D

    Dr. Reddy’s Laboratories Ltd ADR (RDY)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE

    $14.80
    +0.10 (+0.68%)

    Market Cap: $12.29B

    Last updated: Nov 17, 2026 at 4:37 PM ET

    Dr. Reddy’s Laboratories Ltd ADR (RDY) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Dr. Reddy’s Laboratories Ltd ADR (RDY) has a market cap of $12.29B. Its return on invested capital of 5.72% compares with a 11.58% median across 9 similar companies.

    Total Valuation

    Market Cap$12.29B
    Latest price (Nov 17, 2026)$14.80

    Key Dates

    The last ex-dividend date was Jul 24, 2026.

    Last Earnings DateOct 23, 2026
    Last Ex-Dividend DateJul 24, 2026
    Last Payment DateAug 5, 2026
    Fiscal Year EndMarch

    Share Statistics

    The share count rose 0.08% in the quarter ended Sep 30, 2026 and shrank 0.05% a year over 2 years.

    Shares Outstanding833.33M
    Shares Change (YoY)+0.04%
    Shares Change (QoQ)+0.08%
    Share Count Growth (2Y CAGR)-0.05%

    Valuation Ratios

    Sales and book value multiples are 3.5x and 3.1x.

    P/E Ratio39.8x
    P/S Ratio3.5x
    P/B Ratio3.1x
    P/TBV Ratio4.4x
    P/FCF Ratio94.8x
    PEG Ratio9.9

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 22.3x EBITDA and 99.5x free cash flow.

    EV / EBITDA22.3x
    EV / FCF99.5x

    Price Statistics

    The stock is up 6.92% over 52 weeks and trades 12.55% above its 50-day average.

    Beta (1Y)0.35
    52-Week Change+6.92%
    1-Month Change+13.15%
    3-Month Change+22.21%
    6-Month Change+10.82%
    5-Year Change+15.32%
    10-Year Change+43.74%
    Total Return (1Y)+7.99%
    Total Return (3Y CAGR)+4.09%
    Total Return (5Y CAGR)+4.33%
    Return vs SPY (1Y)-5.25%
    Max Drawdown (1Y)-26.01%
    Max Drawdown (3Y)-32.01%
    Sharpe Ratio (1Y)0.23
    Correlation with SPY (1Y)0.18
    50-Day Average$13.15
    200-Day Average$13.24
    52-Week Range$11.28 to $15.49
    RSI (14 Days)69.7
    Average Volume (20 Days)2.79M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.93x current liabilities, and total debt is 0.19x shareholder equity.

    Current Ratio1.93x
    Quick Ratio1.40x
    Debt / Equity0.19x
    Debt / EBITDA1.30x
    Interest Coverage7.23x

    Returns and Efficiency

    Return on invested capital is 5.72% over the last 12 months, against a 5-year average of 13.94%.

    Return on Equity (ROE)7.47%
    Return on Assets (ROA)5.02%
    Return on Invested Capital (ROIC)5.72%
    ROE (5Y Average)16.18%
    ROA (5Y Average)11.17%
    ROIC (5Y Average)13.94%
    Asset Turnover0.59x
    Inventory Turnover2.11x
    Receivables Turnover2.99x
    Cash Conversion Cycle216 days

    Taxes

    Income tax took 21.66% of pretax income over the last 12 months.

    Income Tax (TTM)INR 7.64B
    Effective Tax Rate21.66%

    Scores

    RDY has an Altman Z-Score of 5.78, in the safe zone above 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score5.78
    Altman Z ZoneSafe
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of INR 331.38B over the last 12 months is down 3.15% from the 12 months before.

    RevenueINR 331.38B
    Revenue Growth (YoY)-3.15%
    Gross ProfitINR 163.93B
    Operating IncomeINR 29.56B
    Pretax IncomeINR 35.27B
    Net IncomeINR 28.03B
    EBITDAINR 53.96B

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 67.22% of the INR 577.00B in total assets.

    Working CapitalINR 143.71B
    Shareholder EquityINR 387.87B
    Tangible Book ValueINR 270.21B
    Total AssetsINR 577.00B
    Total LiabilitiesINR 185.92B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After INR 18.10B of capital spending, operating cash flow left INR 12.01B of free cash flow.

    Operating Cash FlowINR 30.11B
    Capital ExpendituresINR 18.10B
    Free Cash FlowINR 12.01B
    Depreciation and AmortizationINR 21.51B
    Dividends PaidINR 6.83B

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 8.92%, against a 5-year average of 19.43%.

    Gross Margin49.47%
    Operating Margin8.92%
    Pretax Margin10.64%
    Net Margin8.46%
    EBITDA Margin16.28%
    FCF Margin3.63%
    Gross Margin (5Y Average)55.93%
    Operating Margin (5Y Average)19.43%
    Net Margin (5Y Average)15.88%

    Growth

    Revenue grew 12.86% a year over 3 years.

    Revenue Growth (3Y CAGR)+12.86%
    Revenue Growth (5Y CAGR)+168.02%
    FCF Growth (3Y CAGR)-7.08%
    FCF Growth (5Y CAGR)+6.76%
    Operating Income Growth (3Y CAGR)-5.08%

    Revenue and profit by year

    Dividends and Yields

    RDY pays out 37.79% of earnings as dividends.

    Dividend Per Share (Annual)$0.06
    Dividend Yield0.43%
    Dividend Growth (3Y CAGR)+5.74%
    Dividend Growth (5Y CAGR)+6.53%
    Payout Ratio37.79%
    FCF Payout Ratio54.81%
    Earnings Yield2.51%
    FCF Yield1.05%

    Full dividend history

    Stock Splits

    The last split was a 5-for-1 forward split on Nov 5, 2024.

    Last Split DateNov 5, 2024
    Split TypeForward split
    Split Ratio5:1

    Peer Position

    Against 10 similar companies, RDY has the 2nd highest P/E.

    P/E Ratio39.8x vs 18.2x median
    P/S Ratio3.5x vs 2.7x median
    ROIC5.72% vs 11.58% median
    Revenue Growth (Trailing 4 Quarters, YoY)-3.15% vs +8.88% median
    Dividend Yield0.43% vs 0.00% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About RDY

    What is RDY's market cap?

    Dr. Reddy’s Laboratories Ltd ADR has a market cap of $12.29B.

    What is RDY's P/E ratio?

    Dr. Reddy’s Laboratories Ltd ADR has a trailing P/E ratio of 39.8x.

    How many shares of RDY are outstanding?

    Dr. Reddy’s Laboratories Ltd ADR has 833.33M shares outstanding. The count is up 0.04% from a year earlier.

    Does RDY pay a dividend?

    Yes. Dr. Reddy’s Laboratories Ltd ADR pays $0.06 a share a year, a dividend yield of 0.43%.